Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the future evaluation of lenalidomide (Revlimid) plus rituximab (Rituxan; R2) in mantle cell lymphoma (MCL).

The results of a 7-year analysis from a multicenter, phase 2 trial (NCT01472562), which were presented virtually during the 2020 ASH Annual Meeting and Exposition, demonstrated high rates of complete responses with R2 as initial treatment in younger and elderly patients with MCL.

Although more data are needed, the durability of these responses suggests that some patients could be cured with R2, says Ruan. A randomized clinical trial should evaluate the combination in a larger patient population vs immunotherapy or BTK inhibitors, which are standard options in MCL, concludes Ruan.